HELIX DIAGNOSTICS
Pharmacogenomics (PGx) Tacrolimus Test
Test Description
Tacrolimus is an immunosuppressant prescribed to patients undergoing organ transplant to reduce risk of organ rejection. Tacrolimus reduces activity of the immune system, leading to reduced risk of organ rejection, specifically for adult patients who have received a kidney, liver, lung, or heart transplant. This drug may also be prescribed to children undergoing organ transplant under specific clinical circumstances.
This test evaluates a patient’s metabolizer status for CYP3A5, which can aid in optimal dosing of tacrolimus to maximize immune suppression efficacy to prevent organ rejection and reduce risk of side effects for transplant patients.
Genes Tested (1)
Important Test Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Blood concentrations and metabolism of tacrolimus are impacted by an individual’s CYP3A5 genotype. This information can help determine appropriate dosing in order to reduce risk of organ rejection leading to improved clinical outcomes for transplant patients.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.